FDA approves Merck’s at-home antiviral pill for COVID-19 treatment
Category: #headlines  | By Nikita Chaurasia  | Date: 2021-12-27 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

FDA approves Merck’s at-home antiviral pill for COVID-19 treatment

The U.S. FDA (Food and Drug Administration) has reportedly approved Merck's antiviral oral medicine for the treatment of COVID-19 among high-risk adult patients. The move comes immediately after the FDA gave a nod to similar treatment from Pfizer for high-risk patients aged 12 years and above.

In a clinical trial of high-risk individuals early in the course of the illness, Merck's medicine, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to cut hospitalizations and deaths by roughly 30%. The decision to approve the drug came after a panel of FDA advisers narrowly voted in support of authorization on November 30.

As per credible sources, oral medication has been indicated for treating mild-to-moderate COVID-19 in adults who are at risk of severe disease and for whom COVID-19 therapies are unavailable or clinically not acceptable.

Both the Merck and Pfizer pills can act as potential tools for COVID-19 patients, particularly to treat the rapidly spreading Omicron variant, which is now dominant in the United States.

Patrizia Cavazzoni, Director of FDA’s Center for Drug Evaluation and Research, was reportedly quoted saying that it is necessary to add to the country's stockpile of COVID-19 medicines via emergency use authorization as new virus types arise.

However, Merck’s molnupiravir is not approved for use in patients under the age of 18 because it can disrupt bone and cartilage formation, claims the FDA.

According to trial results, Pfizer's antiviral regimen, Paxlovid, was approximately 90% effective in reducing hospitalizations and deaths in individuals at high risk of severe illness, which was significantly higher than the efficiency demonstrated by Merck’s drug. This disparity in efficiency rates could hurt Merck’s revenues in the upcoming period.

The U.S government has reportedly signed a contract with Pfizer for 10 million courses at USD 530 per course, while also having a deal with Merck for up to 5 million courses of molnupiravir at USD 700 per course.

Source Credits:

https://economictimes.indiatimes.com/news/international/world-news/u-s-fda-authorizes-mercks-at-home-antiviral-covid-19-pill/articleshow/88457835.cms

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

EasyJet sees a rise in bookings as customers plan their next vacations

EasyJet sees a rise in bookings as customers plan their next vacations

By Nikita Chaurasia

British multinational low-cost airline group, EasyJet, has reported a record surge in bookings for the month of January as people prioritized their travel plans for the coming year. The news comes as airlines world over start to show signs that they&...

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...